Abstract
Kynurenine-3-monooxygenase (KMO) is an important therapeutic target for several brain disorders that has been extensively studied in recent years. Potent inhibitors towards KMO have been developed and tested within different disease models, showing great therapeutic potential, especially in models of neurodegenerative disease. The inhibition of KMO reduces the production of downstream toxic kynurenine pathway metabolites and shifts the flux to the formation of the neuroprotectant kynurenic acid. However, the efficacy of KMO inhibitors in neurodegenerative disease has been limited by their poor brain permeability. Combined with virtual screening and prodrug strategies, a novel brain penetrating KMO inhibitor has been developed which dramatically decreases neurotoxic metabolites. This review highlights the importance of KMO as a drug target in neurological disease and the benefits of brain permeable inhibitors in modulating kynurenine pathway metabolites in the central nervous system.
Original language | English |
---|---|
Journal | Archives of Biochemistry and Biophysics |
Early online date | 1 Dec 2020 |
DOIs | |
Publication status | E-pub ahead of print - 1 Dec 2020 |
Research Beacons, Institutes and Platforms
- Manchester Institute of Biotechnology
Fingerprint
Dive into the research topics of 'Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases'. Together they form a unique fingerprint.Equipment
-
Biochemical and Biophysical Sciences Technology Platform
Heyes, D. (Senior Technical Specialist), Boothman, C. (Senior Technical Specialist), Cliffe, L. (Technical Specialist), Dunstan, M. (Senior Technical Specialist), Golovanova, M. (Senior Technician), Hoeven, R. (Technical Specialist), Lopez Perez, R. (Senior Technician), Sakuma, M. (Senior Technician), Tait, S. (Senior Technician) & Tilakaratna, V. (Senior Technician)
FSE ResearchFacility/equipment: Platform